Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ciprofloxacin + dexamethasone** is a fixed-dose antibacterial and corticosteroid combination, most prominently supplied as an otic suspension containing ciprofloxacin 0.3% and dexamethasone 0.1%. Ciprofloxacin is a fluoroquinolone antibacterial that inhibits bacterial type II topoisomerases, while dexamethasone is a glucocorticoid that suppresses local inflammation. In the United States, the otic product is approved for acute otitis externa in patients aged 6 months and older and for acute otitis media in pediatric patients with tympanostomy tubes. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021537s017lbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciprofloxacin + dexamethasone.